• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

四基因预后特征与肺腺癌脑转移风险

Four-gene Prognostic Signature and Risk of Brain Metastasis of Lung Adenocarcinoma.

作者信息

Gong Zheng, Yu Fengyuan, Li Chen, Zhao Bingying, Wen Miaowei, Zhang Shanshan, Xu Zhezhe, Wu Ailu, Zang Rukun, Li Yuan, Li Hongwei, Song Yipeng

机构信息

Qingdao University, Qingdao, China.

Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.

出版信息

Mol Carcinog. 2025 Jul;64(7):1209-1221. doi: 10.1002/mc.23922. Epub 2025 Apr 13.

DOI:10.1002/mc.23922
PMID:40222041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12183640/
Abstract

Brain metastasis has a high incidence and poor prognosis in lung adenocarcinoma (LUAD). We sought to identify genes associated with LUAD brain metastasis and with the prognosis of patients with LUAD. Differential gene expression analysis was performed on LUAD patients with and without distant metastasis from the Cancer Genome Atlas (TCGA) database and LUAD patients with and without brain metastasis from the GEO GSE14108 and GSE10072 data sets. Subsequently, a LASSO model was constructed using the genes differentially expressed in both analyses to screen for prognostic genes. A risk model based on 11 genes was established by screening prognostic genes. Subsequently, a prognostic prediction model was developed based on the risk model. Expression and survival analysis of the identified genes in metastatic LUAD was assessed. As a result, differential gene expression analysis indicated that compared to primary lung cancer, the expression of CMAS, NEK2, and SHCBP1 was significantly upregulated in metastatic lung cancer, whereas the expression of IL2 was significantly downregulated. Additionally, these genes exhibited strong correlations with the overall survival of LUAD patients. Finally, compared with LUAD patients without brain metastasis, immunohistochemistry analysis verified CMAS, NEK2, and SHCBP1 exhibited increased expression in LUAD with brain metastasis.

摘要

脑转移在肺腺癌（LUAD）中发生率高且预后差。我们试图鉴定与LUAD脑转移以及LUAD患者预后相关的基因。对来自癌症基因组图谱（TCGA）数据库的有和无远处转移的LUAD患者以及来自GEO GSE14108和GSE10072数据集的有和无脑转移的LUAD患者进行差异基因表达分析。随后，使用在两项分析中差异表达的基因构建LASSO模型以筛选预后基因。通过筛选预后基因建立了基于11个基因的风险模型。随后，基于该风险模型开发了预后预测模型。评估了所鉴定基因在转移性LUAD中的表达和生存分析。结果，差异基因表达分析表明，与原发性肺癌相比，CMAS、NEK2和SHCBP1在转移性肺癌中的表达显著上调，而IL2的表达显著下调。此外，这些基因与LUAD患者的总生存期表现出强相关性。最后，与无脑转移的LUAD患者相比，免疫组织化学分析证实CMAS、NEK2和SHCBP1在有脑转移的LUAD中表达增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/e2f232463a82/MC-64-1209-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/036c324a9c90/MC-64-1209-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/4a8b857653ff/MC-64-1209-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/97690dec6c1a/MC-64-1209-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/4627b220e494/MC-64-1209-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/9a363c345d66/MC-64-1209-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/edb4422ba22a/MC-64-1209-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/b045d3b5f54e/MC-64-1209-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/93ab3c5f7a46/MC-64-1209-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/e2f232463a82/MC-64-1209-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/036c324a9c90/MC-64-1209-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/4a8b857653ff/MC-64-1209-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/97690dec6c1a/MC-64-1209-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/4627b220e494/MC-64-1209-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/9a363c345d66/MC-64-1209-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/edb4422ba22a/MC-64-1209-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/b045d3b5f54e/MC-64-1209-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/93ab3c5f7a46/MC-64-1209-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a48b/12183640/e2f232463a82/MC-64-1209-g009.jpg

相似文献

1
Four-gene Prognostic Signature and Risk of Brain Metastasis of Lung Adenocarcinoma.四基因预后特征与肺腺癌脑转移风险
Mol Carcinog. 2025 Jul;64(7):1209-1221. doi: 10.1002/mc.23922. Epub 2025 Apr 13.
2
A novel disulfidptosis-related prognostic gene signature and experimental validation identify as a novel therapeutic target in lung adenocarcinoma.一种新型的与铁死亡相关的预后基因特征及实验验证确定其为肺腺癌中的一个新型治疗靶点。
Cancer Biomark. 2025 Jan;42(1):CBM230276. doi: 10.3233/CBM-230276. Epub 2024 Feb 12.
3
Unraveling the role of GPCR signaling in metabolic reprogramming and immune microenvironment of lung adenocarcinoma: a multi-omics study with experimental validation.揭示GPCR信号在肺腺癌代谢重编程和免疫微环境中的作用：一项具有实验验证的多组学研究
Front Immunol. 2025 Jun 6;16:1606125. doi: 10.3389/fimmu.2025.1606125. eCollection 2025.
4
Integrating multi-omics to unveil PSMD12 as a critical gene in promoting brain metastases of lung adenocarcinoma.整合多组学技术揭示PSMD12作为促进肺腺癌脑转移的关键基因。
J Transl Med. 2025 Jun 17;23(1):668. doi: 10.1186/s12967-025-06680-3.
5
Liquid-Liquid Phase Separation in the Prognosis of Lung Adenocarcinoma: An Integrated Analysis.液-液相分离在肺腺癌预后中的综合分析
Curr Cancer Drug Targets. 2025;25(4):323-334. doi: 10.2174/0115680096345676241001081051.
6
Development of a machine learning-derived dendritic cell signature for prognostic stratification in lung adenocarcinoma.用于肺腺癌预后分层的机器学习衍生树突状细胞特征的开发。
Front Immunol. 2025 Jun 9;16:1621370. doi: 10.3389/fimmu.2025.1621370. eCollection 2025.
7
Development and validation of prognostic models based on cell cycle-related signatures for predicting the prognosis of patients with lung adenocarcinoma.基于细胞周期相关特征的预后模型的开发与验证，用于预测肺腺癌患者的预后
Transl Cancer Res. 2025 May 30;14(5):2900-2915. doi: 10.21037/tcr-24-1479. Epub 2025 May 27.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Construction of a prognostic model for lung adenocarcinoma based on necroptosis genes and its exploration of the potential for tumor immunotherapy.基于坏死性凋亡基因构建肺腺癌预后模型及其肿瘤免疫治疗潜力探索
Transl Cancer Res. 2025 May 30;14(5):2563-2579. doi: 10.21037/tcr-24-2165. Epub 2025 May 26.
10
Integrative metagenomic, transcriptomic, and proteomic analysis reveal the microbiota-host interplay in early-stage lung adenocarcinoma among non-smokers.综合宏基因组学、转录组学和蛋白质组学分析揭示了非吸烟人群早期肺腺癌中微生物组-宿主相互作用。
J Transl Med. 2024 Jul 13;22(1):652. doi: 10.1186/s12967-024-05485-0.

引用本文的文献

1
The multi-omics analysis identifies a novel endoplasmic reticulum stress and immune related genes signature in lung adenocarcinoma.多组学分析确定了肺腺癌中一种新的内质网应激和免疫相关基因特征。
Discov Oncol. 2025 Jul 1;16(1):1190. doi: 10.1007/s12672-025-03033-w.

本文引用的文献

1
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer.白细胞介素-2 信号在自身免疫和癌症中 T 细胞生物学的调节作用。
Immunity. 2024 Mar 12;57(3):414-428. doi: 10.1016/j.immuni.2024.02.001.
2
Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.SHCBP1 抑制剂 AZD5582 在胰腺癌治疗中的治疗潜力。
Cancer Sci. 2024 Mar;115(3):820-835. doi: 10.1111/cas.16059. Epub 2023 Dec 27.
3
SHCBP1 Promotes the Proliferation of Breast Cancer Cells by Inhibiting CXCL2.SHCBP1通过抑制CXCL2促进乳腺癌细胞增殖。
J Cancer. 2023 Oct 16;14(18):3444-3456. doi: 10.7150/jca.88072. eCollection 2023.
4
Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.解析唾液酸对胰腺癌免疫图谱和免疫治疗效果的影响。
J Immunother Cancer. 2023 Nov;11(11). doi: 10.1136/jitc-2023-007805.
5
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2.通过联合使用无毒的 IL-12 和 IL-2 变体克服肺癌免疫治疗抵抗。
JCI Insight. 2023 Oct 9;8(19):e172728. doi: 10.1172/jci.insight.172728.
6
Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway.鲁卡帕尼通过 SHCBP1/CDK1 通路抑制肺腺癌细胞增殖和迁移。
FEBS J. 2023 Dec;290(24):5720-5743. doi: 10.1111/febs.16933. Epub 2023 Aug 28.
7
Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.表达白细胞介素 2 的病毒载体用于癌症免疫治疗。
Hum Gene Ther. 2023 Sep;34(17-18):878-895. doi: 10.1089/hum.2023.099.
8
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.携带 TNFα 和 IL-2 的腺病毒经静脉给药可改善非小细胞肺癌的抗 PD-1 检查点阻断。
Oncoimmunology. 2023 Aug 2;12(1):2241710. doi: 10.1080/2162402X.2023.2241710. eCollection 2023.
9
Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer.NEK2 在胃癌中的分子特征、致癌作用以及相关的免疫和药物基因组学特征。
Int Immunopharmacol. 2023 Mar;116:109737. doi: 10.1016/j.intimp.2023.109737. Epub 2023 Feb 2.
10
Interleukin-2-based therapies in cancer.基于白细胞介素-2的癌症治疗方法。
Sci Transl Med. 2022 Nov 9;14(670):eabo5409. doi: 10.1126/scitranslmed.abo5409.